Form 4: Verve Therapeutics Chief Scientific Officer Troy Lister Reports Stock Option Grant

Troy Lister, Chief Scientific Officer of Verve Therapeutics, reports the acquisition of stock options in the company.

Summary

• On June 21, 2024, Troy Lister, the Chief Scientific Officer of Verve Therapeutics, Inc., was granted stock options to purchase 32,000 shares of common stock at an exercise price of $5.29 per share.
• The options vest over a four-year period, with 25% vesting on June 21, 2025, and the remainder vesting in equal monthly installments until June 21, 2028.
• Following the transaction, Lister directly owns 32,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice, indicating confidence in the company's future performance.

Positives

• The grant of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.

Industry Context

This is a standard practice for incentivizing key executives in publicly traded companies, particularly in the biotechnology sector.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in biotech companies.
• The vesting schedule of 25% after one year followed by monthly installments is fairly standard.
• Comparable companies like CRISPR Therapeutics and Editas Medicine also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could positively impact shareholders by aligning management's interests with the company's long-term success.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates